WO2013091020A3 - Formulation ophtalmique - Google Patents

Formulation ophtalmique Download PDF

Info

Publication number
WO2013091020A3
WO2013091020A3 PCT/AU2012/001595 AU2012001595W WO2013091020A3 WO 2013091020 A3 WO2013091020 A3 WO 2013091020A3 AU 2012001595 W AU2012001595 W AU 2012001595W WO 2013091020 A3 WO2013091020 A3 WO 2013091020A3
Authority
WO
WIPO (PCT)
Prior art keywords
branched
linear
ophthalmic formulation
alkenyl
alkyl
Prior art date
Application number
PCT/AU2012/001595
Other languages
English (en)
Other versions
WO2013091020A2 (fr
Inventor
Thomas Millar
Burkhardt SCHUETT
Original Assignee
University Of Western Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011905421A external-priority patent/AU2011905421A0/en
Priority to KR1020217025498A priority Critical patent/KR20210104916A/ko
Priority to MX2014007629A priority patent/MX364693B/es
Priority to JP2014547635A priority patent/JP6087374B2/ja
Priority to EP18187476.9A priority patent/EP3459929A1/fr
Priority to KR1020147020528A priority patent/KR102080951B1/ko
Priority to EP12860686.0A priority patent/EP2794550B1/fr
Priority to CN201280069966.XA priority patent/CN104271548B/zh
Priority to BR112014015430-9A priority patent/BR112014015430B1/pt
Priority to SI201231543T priority patent/SI2794550T1/sl
Priority to CA2859997A priority patent/CA2859997C/fr
Priority to RU2014129437A priority patent/RU2625301C2/ru
Priority to PL12860686T priority patent/PL2794550T3/pl
Priority to US14/367,836 priority patent/US10385003B2/en
Priority to ES12860686T priority patent/ES2716806T3/es
Priority to AU2012318266A priority patent/AU2012318266B2/en
Priority to KR1020207004568A priority patent/KR102291754B1/ko
Priority to DK12860686.0T priority patent/DK2794550T3/en
Application filed by University Of Western Sydney filed Critical University Of Western Sydney
Publication of WO2013091020A2 publication Critical patent/WO2013091020A2/fr
Priority to ZA2014/04642A priority patent/ZA201404642B/en
Publication of WO2013091020A3 publication Critical patent/WO2013091020A3/fr
Priority to HK15103880.0A priority patent/HK1203480A1/xx
Priority to US16/515,387 priority patent/US20200190015A1/en
Priority to US17/318,581 priority patent/US20210403410A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/24—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds
    • C07C69/26—Synthetic waxes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/58—Esters of straight chain acids with eighteen carbon atoms in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/24—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur une formulation ophtalmique comprenant un composé de formule (I) dans laquelle R1 représente un groupe alkyle en C9-C33 linéaire ou ramifié ou un groupe alcényle en C9-C33 linéaire ou ramifié ayant 1 à 4 doubles liaisons; R2 représente un groupe alkyle en C9-C19 linéaire ou ramifié ou un groupe alcényle en C9-C19 linéaire ou ramifié ayant 1 à 4 doubles liaisons; et un véhicule ophtalmologiquement acceptable.
PCT/AU2012/001595 2011-12-23 2012-12-21 Formulation ophtalmique WO2013091020A2 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
RU2014129437A RU2625301C2 (ru) 2011-12-23 2012-12-21 Офтальмологическая композиция
DK12860686.0T DK2794550T3 (en) 2011-12-23 2012-12-21 Ophthalmic formulation
JP2014547635A JP6087374B2 (ja) 2011-12-23 2012-12-21 眼科用製剤
EP18187476.9A EP3459929A1 (fr) 2011-12-23 2012-12-21 Formulation ophtalmique
KR1020147020528A KR102080951B1 (ko) 2011-12-23 2012-12-21 안과용 제형물
EP12860686.0A EP2794550B1 (fr) 2011-12-23 2012-12-21 Formulation ophtalmique
CN201280069966.XA CN104271548B (zh) 2011-12-23 2012-12-21 眼用制剂
BR112014015430-9A BR112014015430B1 (pt) 2011-12-23 2012-12-21 Compostos, formulações oftálmicas e seus usos
SI201231543T SI2794550T1 (sl) 2011-12-23 2012-12-21 Oftalmološka formulacija
CA2859997A CA2859997C (fr) 2011-12-23 2012-12-21 Formulation ophtalmique
PL12860686T PL2794550T3 (pl) 2011-12-23 2012-12-21 Receptura okulistyczna
KR1020217025498A KR20210104916A (ko) 2011-12-23 2012-12-21 안과용 제형물
AU2012318266A AU2012318266B2 (en) 2011-12-23 2012-12-21 Ophthalmic formulation
ES12860686T ES2716806T3 (es) 2011-12-23 2012-12-21 Formulación Oftálmica
US14/367,836 US10385003B2 (en) 2011-12-23 2012-12-21 Ophthalmic formulation
KR1020207004568A KR102291754B1 (ko) 2011-12-23 2012-12-21 안과용 제형물
MX2014007629A MX364693B (es) 2011-12-23 2012-12-21 Formulacion oftalmica.
ZA2014/04642A ZA201404642B (en) 2011-12-23 2014-06-24 Opthalmic formulation
HK15103880.0A HK1203480A1 (en) 2011-12-23 2015-04-22 Ophthalmic formulation
US16/515,387 US20200190015A1 (en) 2011-12-23 2019-07-18 Ophthalmic formulation
US17/318,581 US20210403410A1 (en) 2011-12-23 2021-05-12 Ophthalmic formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011905421A AU2011905421A0 (en) 2011-12-23 Ophthalmic Formulation
AU2011905421 2011-12-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/367,836 A-371-Of-International US10385003B2 (en) 2011-12-23 2012-12-21 Ophthalmic formulation
US16/515,387 Continuation US20200190015A1 (en) 2011-12-23 2019-07-18 Ophthalmic formulation

Publications (2)

Publication Number Publication Date
WO2013091020A2 WO2013091020A2 (fr) 2013-06-27
WO2013091020A3 true WO2013091020A3 (fr) 2014-09-25

Family

ID=48669621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2012/001595 WO2013091020A2 (fr) 2011-12-23 2012-12-21 Formulation ophtalmique

Country Status (21)

Country Link
US (3) US10385003B2 (fr)
EP (2) EP2794550B1 (fr)
JP (1) JP6087374B2 (fr)
KR (3) KR20210104916A (fr)
CN (1) CN104271548B (fr)
AU (1) AU2012318266B2 (fr)
BR (1) BR112014015430B1 (fr)
CA (1) CA2859997C (fr)
CO (1) CO7101242A2 (fr)
DK (1) DK2794550T3 (fr)
ES (1) ES2716806T3 (fr)
HK (1) HK1203480A1 (fr)
HU (1) HUE042760T2 (fr)
MX (1) MX364693B (fr)
PL (1) PL2794550T3 (fr)
PT (1) PT2794550T (fr)
RU (1) RU2625301C2 (fr)
SI (1) SI2794550T1 (fr)
TR (1) TR201902752T4 (fr)
WO (1) WO2013091020A2 (fr)
ZA (1) ZA201404642B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10385003B2 (en) 2011-12-23 2019-08-20 Thomas Millar Ophthalmic formulation
JP2020525416A (ja) * 2017-06-29 2020-08-27 アドヴァイテ エルエルシー． 眼表面障害の治療及び診断
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
WO2022229441A2 (fr) * 2021-04-30 2022-11-03 Helsingin Yliopisto Combinaison spécifique de lipides ainsi que méthodes et utilisations associées
CN115607534A (zh) * 2021-07-16 2023-01-17 云南拜奥泰克生物技术有限责任公司 一种mlct替代睑酯油及其制备方法
FI20225982A1 (fi) * 2022-11-02 2024-05-03 Univ Helsinki Uudet formulaatiot

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2855047A1 (fr) * 2003-05-19 2004-11-26 Oreal Composition comprenant une base sphingoide, un activateur de la voie des 4-et/ou des 6-hydroxylases et un acide gras, utilisation pour renforcer la fonction barriere de la peau

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455016B2 (en) * 2004-03-12 2013-06-04 Melbj Holdings, Llc Treatment for meibomian gland dysfunction or obstruction
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
CA2679448A1 (fr) * 2007-02-28 2008-09-04 Aciex, Inc. Procedes et compositions permettant de normaliser les secretions des glandes de meibomius
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US10385003B2 (en) 2011-12-23 2019-08-20 Thomas Millar Ophthalmic formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2855047A1 (fr) * 2003-05-19 2004-11-26 Oreal Composition comprenant une base sphingoide, un activateur de la voie des 4-et/ou des 6-hydroxylases et un acide gras, utilisation pour renforcer la fonction barriere de la peau

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUTOVICH, I. ET AL.: "Human Tear Film and Meibum. Very Long Chain Wax Esters and (O-acyl)-omega-hydroxy Fatty Acids of Meibum.", JOURNAL OF LIPID RESEARCH, vol. 50, no. 12, 2009, pages 2471 - 2485, XP055157215 *
WOHLMAN, A.: "Meadowestolide and Meadowlactone: Unique Materials for Skin Care and Pigmented Products.", SURFACTANT SCIENCE SERIES, vol. 135, no. 3RD ED, 2007, pages 357 - 369, XP008174185 *

Also Published As

Publication number Publication date
CO7101242A2 (es) 2014-10-31
PT2794550T (pt) 2019-03-26
EP2794550A2 (fr) 2014-10-29
US20210403410A1 (en) 2021-12-30
SI2794550T1 (sl) 2019-06-28
ES2716806T3 (es) 2019-06-17
KR20210104916A (ko) 2021-08-25
BR112014015430A2 (pt) 2017-06-13
US20200190015A1 (en) 2020-06-18
JP2015506922A (ja) 2015-03-05
PL2794550T3 (pl) 2019-08-30
KR102080951B1 (ko) 2020-05-28
HUE042760T2 (hu) 2019-07-29
CA2859997C (fr) 2016-12-13
EP2794550A4 (fr) 2015-10-21
CN104271548B (zh) 2016-06-08
BR112014015430A8 (pt) 2017-07-04
JP6087374B2 (ja) 2017-03-01
KR20140131504A (ko) 2014-11-13
CA2859997A1 (fr) 2013-06-27
HK1203480A1 (en) 2015-10-30
EP3459929A1 (fr) 2019-03-27
BR112014015430B1 (pt) 2022-03-03
KR20200020973A (ko) 2020-02-26
EP2794550B1 (fr) 2019-02-20
AU2012318266A1 (en) 2013-07-11
ZA201404642B (en) 2016-07-27
MX2014007629A (es) 2015-10-29
RU2625301C2 (ru) 2017-07-13
DK2794550T3 (en) 2019-04-08
TR201902752T4 (tr) 2019-03-21
WO2013091020A2 (fr) 2013-06-27
MX364693B (es) 2019-05-06
RU2014129437A (ru) 2016-02-10
KR102291754B1 (ko) 2021-08-20
CN104271548A (zh) 2015-01-07
US10385003B2 (en) 2019-08-20
US20140377335A1 (en) 2014-12-25
AU2012318266B2 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
WO2013091020A3 (fr) Formulation ophtalmique
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
EP4230631A3 (fr) Procédé de préparation de triflates de silyloxyéthyle trisubstitués
MX368745B (es) Composiciones de tratamiento de baño autoadhesivas.
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
PH12015501082B1 (en) Pyridine -2-amides useful as cb2 agonists
AU2012334173A8 (en) [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
AU2009310099A8 (en) Agricultural compositions
IN2014MN01521A (fr)
WO2013114118A3 (fr) Polymère
WO2012153825A3 (fr) Préparation externe pour la peau et son procédé de fabrication
IN2014DN05972A (fr)
IN2014DN00144A (fr)
MX342273B (es) Proceso para la preparacion de esteres de acido (5-fluoro-2-metil-3-quinolina-2-ilmetil-indol-1-il)-acetico.
BR112013015604A2 (pt) novo derivado de isoquinolina substituído
NZ605804A (en) New aminopyrazoloquinazolines
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
EA201300100A2 (ru) Способ ферментативного синтеза (7s)-3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбоновой кислоты или ее сложных эфиров и применение для синтеза ивабрадина и его соли
MX2015017864A (es) Metodo de preparacion de derivados de acido pirrolidina-2-carboxil ico.
IN2015DN02514A (fr)
IN2014CN04667A (fr)
IN2014CN04922A (fr)
IN2014CN04279A (fr)
WO2013098837A3 (fr) Composé de bis-quinaldine et son procédé de préparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2012318266

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12860686

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2859997

Country of ref document: CA

Ref document number: 2014547635

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14367836

Country of ref document: US

Ref document number: MX/A/2014/007629

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2012860686

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012860686

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20147020528

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14158909

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2014129437

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014015430

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014015430

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140623